Loading
Travere Therapeutics, Inc. Stock: price and insider trades · United States
Travere Therapeutics, Inc.: what insiders have been doing
Travere Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 24 insiders have disclosed 167 filings since 18 October 2025.
All open-market trades in the period are sales: 80 sales worth €68.6M, by 11 insiders, with no purchase on record. The totals do not cover 2 filings with an undisclosed amount. At €5.7M, the sale published on 17 September 2026 by Dube Eric M is the largest of the period (0.12% of market cap).
Compared with its exchange (5,458 companies, median 22 filings), a count of 167 filings is above the norm. Over the whole record (from 2016), the tally stands at no purchases and 141 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 490.7 m USD and net income at -25.5 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
344
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€72M
141 ops. · all time
Who traded when
BuySaleEric M. Dube15 sales
Christopher R. Cline14 sales
Peter Heerma12 sales
Elizabeth E. Reed11 sales
Jula Inrig10 sales
William E. Rote8 sales
+5 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Travere Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$75.21.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,361 of 24,148 companies
30.8
score / 100
Value33
Quality29
FCF yld-0.4%
Earn yld-0.5%
EV/EBITDA·
ROE-236%
Gross mgn98%
Net mgn-5.2%
Debt/EBITDA14.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$52.79
Analyst consensus
14 analystsStrong buy
US$62.00Target US$75.21(+42%)US$90.00
Income statement
RevenueUS$490.7M
Gross profitUS$480.4M98% margin
EBITDAUS$22.2M5% margin
Net income-US$25.5M-7.4% margin
Valuation
PER (forward)9.4x
P/Book203.0x
Beta1.14
Balance sheet & cash
Market capUS$4.9B
Total debtUS$328.7M
Free Cash Flow-US$20.4M
Debt / Equity2516%
Profitability & ownership
ROE-236.4%
ROA-3.7%
% insiders0.7%
% institutions115.3%
Last declaration on 15 October 2026
Declarations344 total
8,282 shares@ US$63.484.7% of flowCommonSEC144:0001950047-26-009625
1,625 shares@ US$20.460.0006% mcap1.1% of flowCommon StockSEC:0001882909-26-000004:2
4,275 shares@ US$62.1350.0047% mcap9.0% of flowCommon StockSEC:0001882909-26-000004:3
400 shares@ US$65.310.0005% mcap0.6% of flowCommon StockSEC:0001943192-26-000006:4
39,283 shares@ US$26.880.019% mcap4.6% of flowCommon StockSEC:0001789617-26-000004:0
1,381 shares@ US$22.400.0006% mcap0.1% of flowCommon StockSEC:0001789617-26-000004:1
36,526 shares@ US$8.930.0058% mcap1.4% of flowCommon StockSEC:0001789617-26-000004:2
93,604 shares@ US$63.24710.11% mcap25.7% of flowCommon StockSEC:0001789617-26-000004:10
37,500 shares@ US$15.460.010% mcap8.1% of flowCommon StockSEC:0001283303-26-000010:0
13,874 shares@ US$62.63260.016% mcap12.1% of flowCommon StockSEC:0001283303-26-000010:2
39,650 shares@ US$17.960.013% mcap3.7% of flowCommon StockSEC:0001698262-26-000005:1
29,021 shares@ US$62.65520.032% mcap9.6% of flowCommon StockSEC:0001698262-26-000005:3
3,000 shares@ US$63.65080.0034% mcap1.0% of flowCommon StockSEC:0001698262-26-000005:4
270 shares@ US$65.310.0003% mcap0.1% of flowCommon StockSEC:0001698262-26-000005:5
57,500 shares@ US$26.880.028% mcap8.1% of flowCommon StockSEC:0001698262-26-000005:8
65,104 shares@ US$63.12050.073% mcap21.6% of flowCommon StockSEC:0001698262-26-000005:9
71,938 shares@ US$62.05170.080% mcap19.4% of flowCommon StockSEC:0001789617-26-000004:3
300 shares@ US$63.66330.0003% mcap0.7% of flowCommon StockSEC:0001882909-26-000004:5
27,473 shares@ US$61.99690.030% mcap39.2% of flowCommon StockSEC:0001943192-26-000006:1
6,802 shares@ US$64.95080.0079% mcap1.0% of flowCommon StockSEC:0001763494-26-000007:10
1,431 shares@ US$65.30930.0017% mcap0.4% of flowCommon StockSEC:0001789617-26-000004:6
79,113 shares@ US$63.65460.090% mcap21.9% of flowCommon StockSEC:0001789617-26-000004:11
400 shares@ US$65.310.0005% mcap0.7% of flowCommon StockSEC:0001902368-26-000008:4
25 of 344 declarations
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker TVTX. Headquartered in San Diego, California, Travere operates as a specialty rare-disease company with a strong focus on nephrology and adjacent orphan-therapy opportunities. The company was founded in 2008 and has evolved into a commercial-stage platform that combines drug development, regulatory execution, and a targeted specialty sales model. Travere describes itself as a company focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases, which frames both its R&D strategy and its market positioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1438533/000143853324000014/travereannualreportars.pdf?utm_source=openai))
Travere’s commercial story is increasingly centered on FILSPARI® (sparsentan), its lead product for rare kidney diseases. Recent company disclosures show meaningful U.S. net product-sales growth into 2026, reflecting stronger uptake and continued commercial momentum. A key milestone came in April 2026, when the FDA granted full approval to FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. That approval broadens the drug’s addressable clinical footprint and reinforces its role as the main value driver in the portfolio. Travere also supports treatment initiation and adherence through Travere TotalCare®, a patient-support program designed for patients, caregivers, and healthcare providers. ([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx?utm_source=openai))
Read moreShow less
From a competitive standpoint, Travere is a focused specialist rather than a scaled diversified pharma company. Its advantage lies in operating within rare diseases, where clinical differentiation, regulatory barriers, and reimbursement complexity can reduce direct competition and support premium pricing when data are compelling. The company’s strategy relies on expanding FILSPARI’s label, converting commercial momentum into durable revenue, and advancing its pipeline and partnerships. Travere has also reported international collaborations, including with Chugai Pharmaceutical in Japan and CSL in parts of Europe, signaling a selective global expansion strategy. That said, the company remains exposed to typical biotech risks: launch execution, payer access, manufacturing scale-up, regulatory outcomes, and competitive dynamics. ([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx?utm_source=openai))
For investors, Travere represents a healthcare/pharma growth story with a rare-disease focus and a commercially important lead asset. The company is not a broad-based pharmaceutical giant; instead, it is a niche specialty player whose equity case depends on FILSPARI adoption, label expansion, international partnerships, and pipeline execution. Recent 2026 updates and quarterly sales trends point to improving fundamentals, while the stock still carries the higher volatility and event risk typical of a specialty biopharma name. ([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
